Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia Schizophreniform or Bipolar I Disorder

  • STATUS
    Recruiting
  • days left to enroll
    89
  • participants needed
    425
  • sponsor
    Alkermes, Inc.
Updated on 29 August 2021
body mass index
bipolar disorder
antipsychotics
mania
olanzapine
aripiprazole
schizophrenia
schizophreniform disorder

Summary

This study will evaluate the effect of ALKS 3831 compared to olanzapine on body weight in young adults with schizophrenia, schizophreniform, or bipolar I disorder who are early in their illness

Description

In the US adolescent subjects starting at age 16 will be enrolled. In the EU, subjects age 18 and older will be enrolled.

Details
Condition Psychosis, Schizophrenia, Schizophrenia and Schizoaffective Disorders, Bipolar I Disorder, Schizophrenia and Schizoaffective Disorders (Pediatric), schizophreniform disorder, schizophrenia disorders
Treatment olanzapine, ALKS 3831
Clinical Study IdentifierNCT03187769
SponsorAlkermes, Inc.
Last Modified on29 August 2021

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note